曲尼司特的抗纤维化作用

近年来，实验和临床研究表明曲尼司特具有抗纤维化作用，它是通过阻止增生成纤维纫胞释放TGF—β、调节其胶原合成而发挥疗效。本文综述曲尼司特在眼科、心肾血管系统、皮肤科等方面的抗纤维化实验研究和临床应用，认为曲尼司特将是纤维化疾病治疗的又一选择。     

Effects of drug serum of anti-fibrosis I herbal compound on calcium in hepatic stellate cell and its molecular mechanism

AIM: To investigate the effects of anti-fibrosis I herbal compound on intracellular Ca2+ in activated hepatic stellate cell (HSC) and to try to survey its molecular mechanism in treatment and prevention of hepatic fibrosis and portal hypertension. METHODS: The activated HSC line was plated on small glass cover slips in 24 wells culture dishes at a density of 5×106 /mL, and incubated in RPMI-1640 media for 24 h. After the cells were loaded with Fluo-3/AM, intracellular Ca2+ was measured with laser scanning confocal microscopy (LSCM). The dynamic changes of intracellular Ca2+, stimulated by carbon tetrachloride, TGF-β1 antibody and the drug serum of anti-fibrosis I herbal compound and under orthogonal design were determined by LSCM. The effect of anti-fibrosis I herbal compound on intracellular Ca2+ was observed before and after the addition of TGF-β1 antibody. RESULTS: The intracellular Ca2+ were significantly different in different dosage of carbon tetrachloride anti-fibrosis I formula drug serum, TGF-β1 antibody and different turn of these substance, but their interval time between CCl4 and TGF-β1 antibody, CCl4 and anti-fibrosis I drug serum had no influence on intracellular Ca2+. The result showed intracellular Ca2+ wasn't significantly different between rat serum without anti-fibrosis I and untreated group. After carbon tetrachloride stimulation, intracellular Ca2+ of activated HSC increased significantly when the dosage of CCl4 from 5 to 15 mmol/L, however, decreased significantly after stimulation by 5-20 μg/mL TGF-β1 antibody or 5-20 mL/L drug serum. Moreover, before and after the addition of TGF-β1 antibody, intracellular Ca2+ was significantly different. These results suggested that the molecular mechanism was independent of blocking TGF-β1 effects. CONCLUSION: Anti-fibrosis I herbal compound may treat hepatic fibrosis and decrease portal hypertension by inhibiting activated HSC contractility through decrease of intracellular Ca2+.     

抗纤维化治疗对大鼠支气管肺泡灌洗液中头孢噻肟浓度的影响

目的观察抗肺纤维化药物对支气管肺泡灌洗液（BALF）中头孢噻肟浓度的影响。方法将90只Wister雄性大鼠随机分成五组,即正常对照组（A组）、模型组（B组）、干扰素组（C组）、盐酸氨溴索组（D组）、地塞米松组（E组）各18只,除A组外均采用气管内注入博来霉素的方法制作肺间质纤维化模型。造模后C、D、E组分别每天腹腔内注入γ-干扰素3万IU/只、盐酸氨溴索7 mg/只、地塞米松0.1 mg/只。各组分别于给药后第7、14、28天,每次取6只大鼠,鼠尾静脉注射头孢噻肟600mg/kg后行支气管肺泡灌洗,取BALF采用液相色谱-质谱联用法测定头孢噻肟浓度,并取肺组织做病理观察。结果第7天D组、E组BALF头孢噻肟浓度低于B组,C组高于B组,E组与B组有显著性差异（P=0.012）。第14天D组、E组BALF头孢噻肟浓度升高,而C组下降,三组均高于B组,D组与B组有显著性差异（P=0.000）。第28天E组头孢噻肟浓度继续升高,明显高于其他各组,而D组锐降,C组继续下降,且均低于B组,C、E组与B组有显著性差异。结论地塞米松可提高纤维化期BALF中头孢噻肟的浓度。     

玉屏风散防治肝病的研究进展

玉屏风散组方为黄芪、白术和防风,具有扶正固表的作用,临床应用广泛,极具开发应用价值。通过查阅近年来有关玉屏风散防治肝病的相关文献,对玉屏风散各组分的肝病防治相关机制、全方防治肝病的临床应用与药理研究进行概括与总结,证实其在肝病的防治中具有调节免疫、抗氧化、抗纤维化;抗肿瘤的作用。     

DCN的研究进展

核心蛋白聚糖（decorin,DCN）是一种与胶原纤维相关的蛋白聚糖,广泛存在于细胞外基质中。DCN可通过多种途经发挥抗纤维化、抗肿瘤等作用,DCN在这些领域的研究应用已成为热点。近年来对DCN作用的研究取得了重大的进展,现作一综述。     

王氏抗肝纤方治疗肝纤维化的实验研究

目的：观察王氏抗肝纤方对肝纤维化的治疗作用及其作用机制。方法：采用二甲基亚硝胺诱导肝纤维化模型,从组织学改变观察王氏抗肝纤方的疗效,以γ干扰素及膈下逐阏汤作为对照组。结果：王氏抗肝纤方对肝纤维化大鼠能显著降低血清ＡＬＴ、ＡＳＴ及肝组织Ｈｙｐ含蛳,减少肝组织中ＣｏｌＩ、ＣｏｌⅣ的沉积和α－ＳＭＡ的表达,提高肝组织间质胶原酶活性。其作用同γ干扰素而明显优于膈下逐瘀汤。结论：王氏抗肝纤方具有较好的抗肝纤     

抗纤胶囊治疗慢性乙型肝炎对肝纤维化指标的影响

目的 :观察抗纤胶囊对慢性乙型肝炎病人肝纤维化的影响。方法 :选择慢性乙型肝炎患者 6 0例 ,随机分为治疗组 30例 ,对照组 30例 ,对照组采用常规保肝降酶治疗 ,治疗组在常规保肝降酶基础上给予抗纤胶囊。疗程 3月。治疗前、后分别检测肝纤维化血清学指标HA、LN、PCⅢ、C -Ⅳ。结果 :治疗组各肝纤维化血清学指标明显下降 ,与对照组比较差异有显著性意义 (P <0 0 5 )。结论 :抗纤胶囊可以减轻和抑制慢性乙型肝炎病人肝纤维化     

饰胶蛋白聚糖的抗纤维化和抗肿瘤作用

饰胶蛋白聚糖（Decorin，DCN）属富含亮氨酸小分子蛋白多糖家族成员之一。大量证据表明：DCN通过结合并中和转化生长因子-β（TGF-β），干扰其与受体结合所致的胞外基质过度沉积，以产生抗纤维化和抑制疤痕形成的作用；DCN亦通过激活EGFR／MAPK／p21信号通路和抑制EGF—EGFR介导的促细胞增殖信号通路等机制，抑制肿瘤细胞增殖与转移。基于DCN以上两方面的生物活性，加之源于人体自身产生，其重组产品免疫原性较低，提示DCN对于慢性纤维化和肿瘤等疾病的防治具有潜在的药用开发价值。     

观察抗纤维化治疗对“无毒”慢乙肝的作用

目的:观察抗纤维化治疗对"无毒"慢乙肝的作用。方法:将128例乙肝肝纤维化患者随机分为治疗组与对照组每组64例;对照组给予常规西药恩替卡韦抗病毒和护肝治疗:治疗组在此基础上加服安络化纤丸,2组均治疗24周为1个疗程,观察2组患者治疗前后主要症状体征、肝功能、肝纤维化血清学指标、肝脏瞬时弹性成像(Fibroscan)检查肝脏硬度值(LSM)。结果:1)综合疗效比较:治疗组显效32例,有效28例,无效4例,总有效率93.75%;对照组分别为19、29、16例,总有效率75%,2组比较差异有统计学意义(t=13.33,P0.05)。2)肝功能及肝纤维化血清学指标改善情况比较:治疗组各项指标的改善均优于对照组,HN与对照组比较,t=8.51,P0.05;HA与对照组比较,t=6.28,P0.05;Iv-C与对照组比较,t=7.32,P0.05;PCⅢ与对照组比较,t=6.19,P0.05。3)肝脏瞬时弹性成像检查肝脏硬度值改善情况:治疗组优于对照组(t=13.60,P=0.01)。结论:抗纤维化治疗乙肝或肝硬化患者有效、安全、可靠,能够显著提高乙肝肝纤维化患者西医常规疗法的综合疗效。